KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...
KORU Medical Systems, Inc.KRMD recently announced that it has submitted a 510(k) premarket notification for FDA clearance to ...
The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...
KORU Medical aims to broaden FreedomEDGE use beyond immunoglobulin indications to reach the oncology infusion centre market.
Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the ...
MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...
Traditionally, isotope dilution kinetic studies of glucose, FFA, and amino acid metabolism in humans have primarily used intravenous infusion (and oral administration when tracing enteral absorption) ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...
J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.
MAHWAH, N.J., October 31, 2024--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing ...